A5053422730- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Systemic Lupus Erythematosus Research
- Healthcare during COVID-19 Pandemic
- Hepatocellular Carcinoma Treatment and Prognosis
- Healthcare Regulation
- Cancer Mechanisms and Therapy
- Biological Research and Disease Studies
Hospital Federal dos Servidores do Estado
2011-2023
Universidade Federal do Rio de Janeiro
2017
Universidade de São Paulo
2017
Universidade Federal de São Paulo
2017
Universidade de Ribeirão Preto
2017
Universidade do Estado do Rio de Janeiro
2011
Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims this study to assess effectiveness safety HCV with DAA real-life world a highly admixed population from Brazil. All Brazilian reference centers invited take part web-based registry, prospectively conducted by the Society Hepatology, outcomes DAAs. Data be collected...
Background: Conflicting data regarding the incidence of hepatocellular carcinoma (HCC) after cure HCV infection with direct-acting antivirals (DAAs) remains. We investigated and risk factors to HCC treatment DAAs followed up for five years. Methods: A total 1075 patients ≥ 18 years were treated from 2015 2019 until 2022. Ultrasonography was performed before each 6 months thereafter. Results: Of total, 51/1075 (4.7%) developed in median 40 (IQR 25–58) months: 26/51 (51%) male, age 60 54–66)...
Mutations located in the 109-amino acid fragment of NS5B are typically associated with resistance to interferon (IFN) and ribavirin (RIB) new antiviral drugs. The prevalence these mutations was examined 69 drug-naïve individuals hepatitis C virus (HCV) infections Rio de Janeiro, Brazil. related non-response IFN/RIB were observed all subtypes studied (1a, 1b, 2b, 3a 4). most common mutation Q309R, present subtypes, except subtype 2b frequency above 20%. D244N detected only A333E 2b. We did...
OBJECTIVE:To evaluate the effectiveness and safety of first-generation protease inhibitors for treatment genotype 1 hepatitis C virus-infected patients at Brazilian reference centers.METHODS: This multicenter cross-sectional study included virus monoinfected treated with Peg-interferon, ribavirin, either boceprevir (n=158) or telaprevir (n=557) between July 2013 April 2014 15 centers in Brazil.Demographic, clinical, virological, adverse events data were collected during follow-up.RESULTS: Of...